Insight Molecular Diagnostics (IMDX) Return on Equity (2016 - 2026)

Insight Molecular Diagnostics has disclosed Return on Equity across 11 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.0%, down 10.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (down 10.0% YoY), and the FY2025 annual result was 0.0%, up 4.0% from the prior year.
• Return on Equity came in at 0.0% for Q1 2026 at Insight Molecular Diagnostics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.1% in Q1 2025 to a low of 0.03% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2024), against an average of 0.01%.
• Across the five-year window, Return on Equity rose 11 bps in 2025 and declined 10 bps in 2026, its largest moves.
• Insight Molecular Diagnostics' Return on Equity stood at 0.01% in 2022, then soared by 89 bps to 0.0% in 2023, then jumped by 9612 bps to 0.1% in 2024, then sank by 95 bps to 0.01% in 2025, then declined by 25 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.03% (Q3 2025), per Business Quant data.